【摘要】 近年来肿瘤的发病率逐年升高,其生存率极低,是全球致死性疾病之一。靶向治疗的成功应用明显改善了肿瘤的治疗。然而,原发性和/或获得性耐药使肿瘤治疗面临巨大挑战,我们亟需新的联合治疗方案。RNA干扰可使基因失活,其单独或联合其他手段将是极具前景的肿瘤治疗手段。它能够提高治愈率,克服目前治疗方案中的耐药问题。人类肿瘤中,肝细胞生长因子(HGF)/c-Met通路是最常发生异常调节的通路。并且在肝癌中,c-Met异常激活与不良预后及耐药均有联系。近几年,越来越多的研究发现针对各种靶点,尤其是针对c-Met的抑制剂以及微小RNAs(microRNAs,miRNAs)。文章将对肝细胞肝癌中靶向调控c-Met,抑制其异常信号的mi RNAs进行综述。更多还原

【Abstract】 Cancer is one of the world’s deadliest diseases,with low survival rates and increasing incidence in recent years.The successful application of target therapy significantly improved the treatment of tumor.However,primary and/or acquired resistance make tumor treatment facing huge challenges,and novel combinational therapies were required.RNA interference mediated gene inactivation.Alone or combined with other current therapies will be a promising approach to cancer treatment.It improves cure rate and overcomes drug resistance in current treatment options.Hepatocyte Growth Factor/c-Met signaling is one of the most frequently dysregulated pathways inhuman cancers.Abnormal c-Met activation is correlated with poor clinical outcomes and drug resistance in hepatocellular carcinoma(HCC).In recent years,a large number of studies have identified several inhibitors specifically targeting c-Met and microRNAs(miRNAs).This review discusses potential use of c-Met targeting mi RNAs,suppressing aberrant c-Met signaling in HCC treatment.更多还原